These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 9385480)

  • 21. Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeter. PISCES (SV14604) Study Group.
    Revicki DA; Moyle G; Stellbrink HJ; Barker C
    AIDS; 1999 May; 13(7):851-8. PubMed ID: 10357386
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party.
    Bartlett JA; Benoit SL; Johnson VA; Quinn JB; Sepulveda GE; Ehmann WC; Tsoukas C; Fallon MA; Self PL; Rubin M
    Ann Intern Med; 1996 Aug; 125(3):161-72. PubMed ID: 8686973
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders.
    Piconi S; Parisotto S; Rizzardini G; Passerini S; Terzi R; Argenteri B; Meraviglia P; Capetti A; Biasin M; Trabattoni D; Clerici M
    Blood; 2011 Sep; 118(12):3263-72. PubMed ID: 21576701
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Zidovudine resistance mutations and human immunodeficiency virus type 1 DNA burden: longitudinal evaluation of six patients under treatment.
    Zazzi M; Catucci M; De Milito A; Romano L; Venturi G; Almi P; Gonnelli A; Rubino M; Valensin PE
    Infection; 1996; 24(6):419-25. PubMed ID: 9007588
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preliminary results in HIV-1-infected patients treated with transfer factor (TF) and zidovudine (ZDV).
    Raise E; Guerra L; Viza D; Pizza G; De Vinci C; Schiattone ML; Rocaccio L; Cicognani M; Gritti F
    Biotherapy; 1996; 9(1-3):49-54. PubMed ID: 8993757
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Zidovudine treatment in patients with primary (acute) human immunodeficiency virus type 1 infection: a randomized, double-blind, placebo-controlled trial. DATRI 002 Study Group. Division of AIDS Treatment Research Initiative.
    Niu MT; Bethel J; Holodniy M; Standiford HC; Schnittman SM
    J Infect Dis; 1998 Jul; 178(1):80-91. PubMed ID: 9652426
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team.
    McKinney RE; Johnson GM; Stanley K; Yong FH; Keller A; O'Donnell KJ; Brouwers P; Mitchell WG; Yogev R; Wara DW; Wiznia A; Mofenson L; McNamara J; Spector SA
    J Pediatr; 1998 Oct; 133(4):500-8. PubMed ID: 9787687
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genotypic resistance to zidovudine as a predictor of failure of subsequent therapy with human immunodeficiency virus type-1 nucleoside reverse-transcriptase inhibitors.
    Venturi G; Romano L; Catucci M; Riccio ML; De Milito A; Gonnelli A; Rubino M; Valensin PE; Zazzi M
    Eur J Clin Microbiol Infect Dis; 1999 Apr; 18(4):274-82. PubMed ID: 10385016
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group Protocol 306 Investigators.
    Kuritzkes DR; Marschner I; Johnson VA; Bassett R; Eron JJ; Fischl MA; Murphy RL; Fife K; Maenza J; Rosandich ME; Bell D; Wood K; Sommadossi JP; Pettinelli C
    AIDS; 1999 Apr; 13(6):685-94. PubMed ID: 10397563
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. Amprenavir PROAB2002 Study Team.
    Haubrich R; Thompson M; Schooley R; Lang W; Stein A; Sereni D; van der Ende ME; Antunes F; Richman D; Pagano G; Kahl L; Fetter A; Brown DJ; Clumeck N
    AIDS; 1999 Dec; 13(17):2411-20. PubMed ID: 10597783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.
    Sperling RS; Shapiro DE; Coombs RW; Todd JA; Herman SA; McSherry GD; O'Sullivan MJ; Van Dyke RB; Jimenez E; Rouzioux C; Flynn PM; Sullivan JL
    N Engl J Med; 1996 Nov; 335(22):1621-9. PubMed ID: 8965861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
    Staszewski S; Loveday C; Picazo JJ; Dellarnonica P; Skinhøj P; Johnson MA; Danner SA; Harrigan PR; Hill AM; Verity L; McDade H
    JAMA; 1996 Jul; 276(2):111-7. PubMed ID: 8656502
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.
    Idoko JA; Akinsete L; Abalaka AD; Keshinro LB; Dutse L; Onyenekwe B; Lhekwaba A; Njoku OS; Kehinde MO; Wambebe CO
    West Afr J Med; 2002; 21(2):83-6. PubMed ID: 12403023
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, double-blind, controlled trial. Bristol-Myers Squibb Stavudine/019 Study Group.
    Spruance SL; Pavia AT; Mellors JW; Murphy R; Gathe J; Stool E; Jemsek JG; Dellamonica P; Cross A; Dunkle L
    Ann Intern Med; 1997 Mar; 126(5):355-63. PubMed ID: 9054279
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Zidovudine plus interferon-alpha versus zidovudine alone in HIV-infected symptomatic or asymptomatic persons with CD4+ cell counts > 150 x 10(6)/L: results of the Zidon trial. Zidon Study Group.
    Fernández-Cruz E; Lang JM; Frissen J; Furner V; Châteauvert M; Boucher CA; Dowd P; Stevens J
    AIDS; 1995 Sep; 9(9):1025-35. PubMed ID: 8527074
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.
    Volberding PA; Lagakos SW; Koch MA; Pettinelli C; Myers MW; Booth DK; Balfour HH; Reichman RC; Bartlett JA; Hirsch MS
    N Engl J Med; 1990 Apr; 322(14):941-9. PubMed ID: 1969115
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Placebo-controlled trial to evaluate zidovudine in treatment of human immunodeficiency virus infection in asymptomatic patients with hemophilia. NHF-ACTG 036 Study Group.
    Merigan TC; Amato DA; Balsley J; Power M; Price WA; Benoit S; Perez-Michael A; Brownstein A; Kramer AS; Brettler D
    Blood; 1991 Aug; 78(4):900-6. PubMed ID: 1831059
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
    Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
    Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS.
    AIDS; 1998 Oct; 12(14):F151-60. PubMed ID: 9792371
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Soluble tumor necrosis factor receptors as surrogate markers for the assessment of zidovudine treatment in asymptomatic HIV-1 infection.
    Godfried MH; van der Poll T; Mulder JW; Weverling GJ; Endert E; Lange JM; Sauerwein HP
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Dec; 10(5):531-9. PubMed ID: 8548332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.